A 12-week, Randomized, Single-blind, Placebo-controlled, Multi-centre, Parallel Group, Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 After 4 and 12-weeks of Treatment in Patients With Coronary Artery Disease (CAD)

Trial Profile

A 12-week, Randomized, Single-blind, Placebo-controlled, Multi-centre, Parallel Group, Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 After 4 and 12-weeks of Treatment in Patients With Coronary Artery Disease (CAD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs AZD 5718 (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms FLAVOUR
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2018 Planned number of patients changed from 138 to 200.
    • 10 May 2018 Planned number of patients changed from 200 to 138.
    • 10 May 2018 Planned End Date changed from 25 Sep 2018 to 31 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top